Abstracts Archive - Page 99 of 1683 - ATC Abstracts

2022 American Transplant Congress
Targeted Delivery of Costimulation Inhibitor to Lymph Nodes Promotes Transplant Tolerance via Fibroblastic Reticular Cells
J. Zhao¹, S. Jung¹, X. Li¹, H. Zhang¹, S. Movahedi¹, V. Kasinath¹, M. Uehara¹, J. Azzi¹, P. Sage¹, S. Tullius¹, J. S. Bromberg², R. Abdi¹
¹Brigham and Women's Hospital, Boston, MA, ²University of Maryland School of Medicine, Baltimore, MD
*Purpose: The lymph node (LN) is the primary site of alloimmunity activation and regulation during transplantation. Fibroblastic reticular cells (FRCs), the prominent cells of the…
2022 American Transplant Congress
Social Determinants of Health Impact Successful Listing for Liver and Kidney Transplant
J. B. Henson, D. Mohottige, J. M. Wilder, A. J. Muir, L. M. McElroy
Duke University, Durham, NC
*Purpose: To evaluate the association between community socioeconomic disadvantage and structural social determinants of health (SDOH) on successful listing for liver (LT) and kidney transplantation…
2022 American Transplant Congress
Autophagy is an Important Factor in the Development of Fibrosis Following Renal Injury; Implications for Post-Transplant IFTA
R. Lopez-Soler¹, X. Ding², Q. Zang³
¹Tansplant, Surgery, Edward Hines VA Medical Center, Hines, IL, ²Pathology, Loyola University Medical Center, Maywood, IL, ³Surgery, Loyola University Medical Center, Maywood, IL
*Purpose: Interstitial Fibrosis and Tubular Atrophy (IFTA) is the most common cause of long-term graft failure following renal transplant. There is currently no effective therapy.…
2022 American Transplant Congress
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
A. Sen¹, J. Enriquez¹, M. Rao¹, M. Glass¹, Y. Balachandran¹, S. Syed¹, C. Twist¹, K. Weinberg¹, S. D. Boyd¹, D. Bernstein¹, A. Trickey¹, D. Gratzinger¹, B. Tan¹, M. G. Lapasaran¹, M. A. Robien², M. Brown³, B. Armstrong⁴, M. Sever⁴, D. Desai⁵, G. Mazariegos⁶, C. Chin⁷, T. Fishbein⁸, R. S. Venick⁹, A. Tekin¹⁰, H. Zimmermann¹¹, R. U. Trappe¹², C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
¹Stanford U, Palo Alto, CA, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴Rho, Durham, NC, ⁵UT Southwestern, Dallas, TX, ⁶Pittsburgh U, Pittsburgh, PA, ⁷CCHMC, Cincinnati, OH, ⁸Georgetown U, Washington, DC, ⁹UCLA, LA, CA, ¹⁰Miami U, Miami, FL, ¹¹DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany, ¹²Charité - Universitätsmedizin, Berlin, Germany
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…
2022 American Transplant Congress
Disparities in Liver Transplantation in Patients with HCC Diagnosis
C. Warren¹, A. Zarrinpar²
¹Surgery, University of Florida Shands Health, Gainesville, FL, ²Surgery, University of Florida Health Shands, Gainesville, FL
*Purpose: Disparities in outcomes of hepatocellular carcinoma (HCC) have not been adequately studied, especially in the context of liver transplantation (LT). We sought to identify…
2022 American Transplant Congress
Comparison of Statin-Associated Adverse Events Across Different Types of Statins in Kidney Transplant Recipients
S. Bae¹, J. Ahn², M. A. Schnitzler³, K. Lentine⁴, D. Segev¹, M. McAdams-DeMarco¹
¹Johns Hopkins University, Baltimore, MD, ²SOM, Johns Hopkins University, Baltimore, MD, ³Surgery, Saint Louis University, St. Louis, MO, ⁴Saint Louis University, St. Louis, MO
*Purpose: Statins are the third most prescribed drug class in kidney transplant (KT) recipients. Statin’s safety profile in KT recipients remains unclear, although these individuals…
2022 American Transplant Congress
Increased Regulatory T-cells in Tumor Microenvironment is Associated with Hepatocellular Carcinoma Differentiation in Patients Undergoing Liver Transplantation
G. Orozco¹, R. Gedaly², L. Turcios², F. Marti²
¹Surgery, University of Kentucky, Lexington, KY, ²UKHC, Lexington, KY
*Purpose: Tumor-infiltrating lymphocytes are an essential component of the tumor microenvironment. The balance between cytotoxic effector T cells and immunosuppressive regulatory T cells is critical…
2022 American Transplant Congress
Long Term Analysis of Pediatric En-Bloc Kidney Transplantation: A Single Center Experience
H. H. Patel¹, P. Di Cocco², J. Almario², A. Fratti², S. Akshelyan², E. Benedetti², I. Tzvetanov², M. Spaggiari²
¹University of Missouri-Kansas City School of Medicine, Kansas City, MO, ²University of Illinois at Chicago, Chicago, IL
*Purpose: Pediatric en-bloc kidney transplantations for adult recipients are uncommonly performed due to unique donor characteristics, the technical challenge of the operation, and potential surgical…
2022 American Transplant Congress
Early Clinical Experience With Alvr109, A Partially Hla-matched Sars-cov-2 Specific T-cell Therapy, In Immunocompromised Patients With Covid-19
G. Haidar¹, J. Jacobs², K. Hughes², K. McCormick², A. Naqvi², M. Agha², T. Bogdanovich², B. Johnson², J. Kozar², E. Lendermon², C. Marino², A. Raptis², F. Silveira², W. Marshall³, M. Miller³, E. Atillasoy³, J. Mellors²
¹University of Pittsburgh, Pittsburgh, PA, ²UPitt, Pittsburgh, PA, ³Allovir, Waltham, MA
*Purpose: Therapies for COVID-19 in immunocompromised (IC) patients (pts), including transplant (tx) pts, are limited. We describe our experience with ALVR109, an allogeneic, partially HLA-matched…
2022 American Transplant Congress
The Association of Pre-Transplant Dialysis Time and the Survival Benefit of Deceased Donor Kidney Transplantation
W. F. Parker¹, Y. Becker², R. Gibbons¹
¹University of Chicago, Chicago, IL, ²University of Chicago, Hinsdale, IL
*Purpose: The US Kidney Allocation System (KAS) allows for deceased donor kidney transplant (DDKT) candidates not yet on dialysis to accrue waiting time points by…